Skeletal myopathies have been suggested as a non-cardiac cause of elevations of cardiac troponin (cTn), particularly cardiac troponin T (cTnT). This is of major clinical relevance and concern as cTn plays a major role in the early diagnosis of myocardial infarction (MI). While both the incidence as well as the true pathophysiology (cardiac versus non-cardiac) underlying elevations in cTn in skeletal myopathies remain largely unknown, reexpression of cTnT in regenerating adult skeletal muscle has been suggested as a possible contributor. However, unequivocal protein characterization in skeletal muscle and quantification of the relative amounts of this possible signal versus the cTn signal derived from true cardiomyocyte injury remains elusive. Alternatively, minor cross-reactivity of the cTnT (and possibly at times also cTnI) detection and capture antibodies used in current monoclonal immunoassays with the skeletal troponin T or I isoform may be considered. Both would represent "false positive" elevations from a clinical perspective and would need to be reliably differentiated from "true positive elevations" from subclinical cardiomyocyte injury not detectable by currently available imaging techniques such as echocardiography and contrast enhanced magnetic resonance imaging (MRI), which have at least a 5 times lower sensitivity for cardiomyocyte injury. This review aims to explore the currently available data, its methodological limitations and provide guidance to clinicians to avoid misinterpretation of cTn concentrations.
Introduction
Cardiac troponins (cTn) are regarded as the preferred biomarkers for the diagnosis of myocardial infarction (MI) due to their unique specificity for myocardial cell necrosis and a superior sensitivity than creatine kinase (CK) or its myocardial band isoform (CK-MB) [1, 2] . Although cTn are specific for myocardial injury, abnormal concentrations are not restricted to acute MI (AMI) but may occur with non-ischemic cardiac diseases [3] [4] [5] . Although the introduction of increasingly sensitive cTn assays has enabled an earlier and more accurate diagnosis of MI, the gain in analytical sensitivity has caused a substantial decrease of clinical specificity that worries many physicians and laboratory experts [6, 7] . For this reason, the universal definition of MI [2] demands not only the presence of a cTn concentration above the 99th percentile of a healthy reference population but also a rise and or fall of cTn indicating an acute myocardial injury, together with the presence of symptoms or clinical signs of myocardial ischemia reestablishing cardiac specificity [2] . Reasons for an acute or chronic myocardial injury in the absence of an acute coronary syndrome (ACS) are numerous in the symptomatic patient visiting an emergency department (ED) [3] [4] [5] [6] . Along with other more frequently encountered differential diagnoses for an elevated cTn, chronic skeletal muscle disease has been claimed to represent a potential cause of "false positive" cTnT elevation, particularly when the high sensitivity (hs)TnT assay is used [8] [9] [10] [11] [12] . Whether elevated concentrations of cTnT in blood are due to an analytically correct detection of fetal TnT which is re-expressed in chronically damaged skeletal muscle [13] [14] [15] [16] , or due to cross-reactivity between skeletal troponin and cTn [17] , or due to concomitant cardiac involvement of myopathies [18] , or due to structural heart disease unrelated to skeletal muscle disease has been the subject of debate for many years [18, 19] . Here, we present a critical appraisal on study findings and hypotheses.
What is the evidence for a re-expression of cTnT or cTnI in skeletal muscle disease?
The ontology of cTnI and cTnT is very different. During embryonic and fetal development, skeletal TnI is expressed exclusively in the heart in lieu of cTnI. The expression of this fetal isoform is downregulated and switched to cTnI at approximately 8-9 months postnatally [20] [21] [22] . The case for cTnT is more complex as four distinct cTnT isoforms are generated via alternative splicing (designated cTnT1-4 numbered in order of decreasing molecular size), where cTnT3 is the dominant isoform in the normal adult heart. cTnT is expressed both in skeletal and cardiac tissue until mid-fetal development. Thereafter, terminal differentiation is initiated, and the gene is suppressed in skeletal muscle and upregulated in myocytes [14] . Consistently, Western blot analysis demonstrate the expression of cardiac cTnT isoforms in low abundance in fetal skeletal muscle relative to seven fast skeletal muscle TnT isoforms [13] . However, no cardiac isoforms are present in adult skeletal muscle. Whether fetal isoforms of cTnT can be re-expressed in skeletal muscle postnatally under certain pathological circumstances causing "false positive" results is a matter of debate that is being fostered by a group of investigators who insistently report the existence of such a re-expression in regenerating skeletal muscle cTnT [8, 9, 11] . Some evidence was derived from regenerating skeletal muscle from rats [15] and chickens [14, 16] using immunoblotting and immunohistochemistry without further characterization of protein bands. A summary of human studies [8-12, 17, 23, 24] on the expression of cTnT and cTnI in skeletal muscle diseases is provided in Table 1 .
Bodor et al. [8] reported the detection of cTnT in skeletal muscle of eight of 13 patients with polymyositis and all six patients with Duchenne muscular dystrophy (DMD) using immunohistochemistry. Patients neither underwent screening for cardiac involvement nor were concentrations of cTnT or cTnI measured in the blood. Unexpectedly, fetal cTnT was also found in muscle biopsies of non-diseased skeletal muscle questioning the specificity of the monoclonal antibodies [8] . Using recombinant real-time polymerase chain reaction (RT-PCR), Ricchiuti and Apple [11] reported a cTnT isoform expression at the mRNA level in adult human skeletal muscle obtained from patients with end stage renal disease (ESRD) and DMD. The amplicons obtained by RT-PCR from heart and skeletal muscle mRNAs were compared using DNA sequencing and a sequence comparison software program. Surprisingly, the positive bands on the Western immunoblots in patients with renal-induced myopathy differed in molecular weight between the monoclonal detection and capture (M11.7 and M7) antibodies. Two other studies found cTnT [23, 25] and surprisingly also cTnI-mRNA [23] expression in skeletal muscle but did not assess protein expression. In particular, Messner et al. [23] found cTnT-mRNA in seven skeletal muscle biopsy specimens (six patients with DMD, one patient with a primary sarcoglycanopathy), and unexpectedly also cTnI-mRNA in six individuals (five patients with DMD, one patient with a histologically negative biopsy). Wens et al. [12] reported on 122 patients with Pompe's disease. They detected mRNA of cTnT and a tryptic peptide specific for cTnT by mass spectrometry in skeletal muscle.
Jaffe et al. [9] described 18 patients with myopathies and elevated cTnT collected at the Mayo Clinic. Patients were screened for cTnT, but cTnI (Siemens Stratus CS) was only measured in those with an elevated cTnT prohibiting an unbiased comparison. Skeletal muscle biopsy was only available in four patients of whom only one patient had a facio-scapulo-humeral muscular dystrophy (FSHMD), while the other patients had inflammatory (n = 1), necrotizing/autoimmune-mediated disease (n = 1), or inclusion body myositis (n = 1). At that times, all four patients were regarded as being free of cardiovascular or coronary heart disease. However, only one patient underwent a nuclear stress test (sestamibi scan) to exclude significant coronary artery disease (CAD) while a systematic echocardiographic and MRI evaluation was not performed. Nowadays, patients with arthritis (patient #2), with lymphoma or leukemia (patient #3 and #4), and patients with coronary risk factors and atypical chest pain (patient #1) are viewed at potentially higher risk for cardiovascular disease (CVD) or CAD and would require more extensive screening to fully exclude myocardial disease. Finally, whether the stain in the Western blot depicted in figure 2 of that article truly represents cTnT has been questioned previously [18] as bands appeared faintly between 34 and 36 kDa and not at the 37-39 kDa band that was seen in non-diseased heart muscle biopsies. Furthermore, skeletal muscle samples were not probed for cTnI re-expression. Finally, no confirmatory protein sequencing of the protein band was undertaken. Thus, it is impossible to prove the re-expression of troponin T in skeletal muscle, or to exclude expression of cTnI by these experiments.
Rittoo et al. [10] reported on 52 patients with 20 different types of acquired and inherited neuromuscular diseases. Serial measurements (265 samples) were obtained from 27 initially hospitalized patients showing low levels of persisting hsTnT (4th generation in three of 27 patients) elevations. In contrast, cTnI, measured using two sensitive assays (Siemens cTnI ultra, Roche cTnI), was persistently normal in all but one patient.
Western blotting had a different molecular weight as compared with cTnT in heart muscle (figure 2 of their article). For the soleus muscle extract, two peptides were heavily stained using the monoclonal cTnT antibody M7, and these peptides had molecular weights much lower than cTnT (figure 3 of their article). Interestingly, the skeletal muscle samples were not probed for cTnI re-expression to prove re-expression of cTnT or exclude re-expression of cTn I in skeletal muscle by these experiments. Only sequencing of the proteins that were stained by the antibodies in the Western blot would have been clarified if indeed a cTnT fragment or much more likely an unspecific binding of the antibodies in tissue sections could explain the staining in the Western blot. Consistently, Hämmerer-Lercher et al. [24] found no evidence of either cTnI or cTnT protein expression in skeletal muscle samples of patients with DMD or in an animal model of DMD using Western blot analysis of human or mouse homogenized muscle specimens, despite strong signals for sTnT isoforms. Thus, in general, studies based on Western blot analysis and immunohistochemistry use antibodies that are either not well characterized, miss information on possible cross-reactivities with other troponin isoforms, or lack information on which epitopes of the TnT isoforms were recognized by these antibodies [24] .
Other methods to detect re-expression of fetal cTnT have been reported, particularly expression of messenger RNA in skeletal muscle. However, it has remained unclear if cTnT messenger RNA was quantitatively translated to protein [12, 23] .
More recently, Schmid et al. [17] evaluated 74 patients with known skeletal myopathies of various types and measured hsTnT and the Abbott hsTnI in blood along with a mass spectrometric analysis of protein expression in muscle biopsies. They found that hsTnT was elevated above the 99th percentile in 70% while hsTnI was elevated only in 4% of these patients, respectively. Among the entire study cohort, 15% had a rising and/or falling pattern of hs-cTnT suggestive of acute myocardial injury, and 30% would have met the criteria for MI in the appropriate clinical situation with the present European Society of Cardiology algorithm [26] . This study compared for the first time hsTnT directly with another hsTnI assay. In addition, cardiac MRI and computed tomography were used in a large proportion of patients to exclude underlying cardiovascular pathologies. However, positive bands were found in both diseased and healthy skeletal muscle at molecular weights approximately 5 kDa below cTnT, and liquid chromatography tandem mass spectrometry identified the presence of skeletal troponin T isoforms in these bands [17] . Therefore, it still remains elusive whether elevated hsTnT is due to re-expression of fetal cTnT, or rather it is due to cross-reactivity against skeletal isoform, or even "true" cardiomyocyte injury below the detection threshold of current MRI sequences. Of interest, a small extent of cross-reactivity was also observed for the Abbott hsTnI assay.
There are several possible explanations for the different prevalence of elevated hsTnT and hsTnI in blood. First, there is evidence that the 99th percentile value used to define normality may have been established inappropriately for hsTnI [27] [28] [29] [30] . This hypothesis is supported by several findings in the literature including considerably lower 99th percentile values in normal reference studies than is reported by the manufacturer [31, 32] . In an Australian cohort of healthy individuals, the 99th percentile of the Abbott hsTnI was less than half the approved clinical decision values (CDV) for this assay [27] . In consistency, considerably lower general and sex-specific 99th percentile values have been reported by others [28] [29] [30] . In addition, a multicenter trial among 2300 consecutive patients with suspected AMI reported that approved CDVs for the Abbott hsTnI and Roche hsTnT were not biologically equivalent and could therefore contribute to inconsistencies in the diagnosis of AMI [33] . In support of this speculation on a inappropriately high 99th percentile in healthy subjects [27] , Wildi et al. [33] reported that the biologically equivalent hs-cTnI value corresponding to the CDV for hs-cTnT was less than half the approved CDV for hs-cTnI, an observation consistent with a 99th percentile value half of what is reported by the manufacturer [27] . Second, a previous report noted a similar number of non-ST-elevation myocardial infarction (NSTEMI) diagnoses but a considerably higher prevalence of elevated hsTnT among patients without an ACS suggesting a different epitope specificity of the hsTnT and hsTnI assay [34, 35] . Third, while the Abbott hsTnI seems to have little crossreactivity with skeletal muscle TnI, extrapolation of this finding to all commercially available cTnI assays is not justified because theoretically cross-reactivity between sTnI and cTnI is at least as likely as with cTnT due to homologies of both troponins with skeletal troponin exceeding 50% [36, 37] . Due to the complexity of antibody pairs and a lack of standardization, it is currently not known what commercial assays actually detect [36] . Therefore, future studies need to evaluate potential cross-reactivity with sTnI comparing multiple if not all commercially available cTnI assays head-to-head.
Which is the most appropriate reference method to detect subclinical structural heart disease?
The observation that cTnT, and less often cTnI is elevated in blood in some patients with skeletal muscle myopathy or dystrophy is interesting and it is a matter of debate whether the reason is cross-reactivity with skeletal TnT or TnI, re-expression of fetal TnT in regenerating skeletal muscle or merely due to undetected underlying structural or functional heart disease, obstructive CAD, or arrhythmias including atrial fibrillation among patients with most dystrophinopathies or glycogen storage diseases.
The presence of elevated cTn and particularly hsTn in the blood of community-dwelling adults aged 65 years or older free of CVD has been reported to be associated with structural heart disease [38] , and a higher risk for incident [39] . For years, an obvious discordance between post-procedural increases of cTn or hsTn following elective percutaneous coronary intervention (PCI) and detectable myocardial scar have stimulated a debate about the appropriate threshold of hsTn to diagnose post-procedural myocardial injury or a type 4 MI [2, 40, 41] . Cardiac MRI is less sensitive to detecting myocardial scaring than hsTn [40, 42] questioning the role of contrast-enhanced cMRI as the reference method. Schmacht et al. [43] evaluated whether subclinical cardiac involvement in diabetes mellitus type 2 (DM2) is already detectable in preserved left ventricular function by cardiovascular magnetic resonance. They examined 22 patients with a genetically confirmed diagnosis of DM2 and 17 healthy age-and sex-matched controls using a 1.5 T magnetic resonance imaging (MRI) and reported a high prevalence of structural abnormalities among patients with normal transthoracic echocardiography. Late gadolinium enhancement (LGE) located sub-epicardial basal inferolateral was detectable in 22% of the patients. Extracellular volume was increased in this region and in regions with no focal fibrosis. New cMRI techniques, such as post-contrast myocardial T1 mapping, have been used in DMD to detect diffuse myocardial fibrosis that may escape visualization using standard T1-contrast acquisition [44] . Myocardial fibrosis, assessed by LGE, may be observed, even if the echocardiographic evaluation remains normal [45] [46] [47] [48] . Likewise, new echocardiographic techniques, using transmural strain profile (TMSP), can detect subclinical left ventricular(LV) dysfunction in patients with DMD without wall motion abnormalities by conventional echocardiography [49] . In Becker muscular dystrophy (BMD), the clinical presentation is usually characterized by early right ventricular (RV) dysfunction and is later associated with LV impairment [44] . In the majority of these patients, a structural heart disease would also have been missed with MRI, unless more sophisticated techniques had been applied. Cardiac disease is a common clinical manifestation of neuromuscular disorders, particularly of muscular dystrophies [50] , affecting heart muscle cells as well as specialized conducting myocardial fibers. The prevalence of cardiac involvement in inherited myopathies and muscular dystrophies is variable depending on the underlying pathology. For cardiac involvement in FSHMD, clinical cardiac involvement in 5-27% of the FSHMD patients has been described [51, 52] . Therefore, in the absence of a more sensitive imaging method, an elevation of hsTnT in such patients requires attention and should rather be attributed to early subclinical manifestation of systemic disease than the result of cross-reactivity with skeletal TnT or TnI, or due to re-expression of cTnT in regenerating skeletal muscle.
Is the term "false positive cTnT elevation" correct or misleading?
High sequence homology of 56.6-58.3% (Figure 1 ) between cTnT and sTnT has been reported [36, 37] . Accordingly, Box 1 -The existence of re-expression of cTnT or troponin I in chronically diseased or regenerating skeletal muscle in the adult has not been proven scientifically beyond doubt. -All cTn assays theoretically can exhibit cross-reactivity towards skeletal muscle due to large and diffusely disseminated homologies between the cardiac and the skeletal troponin isoform. However, cross-reactivity with skeletal troponin has been minimized in commercially available to a theoretical level due to meticulous epitope selection and assay engineering. -The most probable reason for elevated cTn in patients with chronic skeletal muscle disease, particularly muscular dystrophies, is cardiac involvement that is very common and often remains subclinical.
Box 2
-cTn, particularly the high sensitivity assay generations are the most sensitive biomarkers indicating myocardial injury. -Accordingly, an elevation of hsTnT or hsTnI in a patient with a chronic skeletal muscle disease including muscular dystrophies requires attention and should rather be attributed to early subclinical manifestation of systemic disease than the result of cross-reactivity with skeletal TnT or TnI, or due to re-expression of cTnT in regenerating skeletal muscle, even if the imaging test appears normal.
clinically relevant cross-reactivity between cTn and skeletal troponin isoforms were reported using the first generation cTnT assay. At that time, Siegel et al. [53] reported that nine of 45 asymptomatic marathon runners showed an increase of cTnT. Since then, the cTnT assay has undergone several modifications abolishing cross-reactivity after the assay was reformulated with new antibodies [54] [55] [56] [57] . The immunoassay was further optimized using monoclonal capture (M11.7 for 4th generation, 5D8 for 5th generation) and detection (M7) antibodies directed against the centrally located epitope [36, 58] . Specifically, M7 recognizes residues 125-131 and 5D8, the chimeric antibody derived from M11.7, recognizes residues 136-147 of the cTnT protein sequence. In the 5th generation hsTnT assay, the M11.7 capture antibody has been re-engineered, with the constant C1 region of the antigen-binding fragment (Fab) being replaced by a human immunoglobulin (IgG) C1 region to produce a mouse-human chimeric detection antibody to minimize the confounding effects of heterophilic anti-mouse antibodies [58] . This antibody selection corresponds to the cardio-specific sequences that have no sequence homology to fetal TnT [58] . With the 5th generation hsTnT, cross-reactivity with human skeletal muscle troponin (sTn) T is being given in the package insert as being below 0.003% (https://www.accessdata.fda.gov/ cdrh_docs/reviews/K162895.pdf), [59] , and no crossreactivity was reported in vitro when skeletal muscle TnT was added to pooled lithium heparin plasma samples at a concentration of 60,000 ng/L (59; package insert). In vivo, the 4th generation assay did not show cross-reactivity despite extreme elevations of CK activity after an ultramarathon over a distance of 216 km [60] , and despite the occurrence of severe rhabdomyolysis with a peak CK of 27,951 U/L in one runner.
In an analogy with cTnT, there is a high homology between 40 and 52% (Figure 1 ) between cTnI and sTnI, sparing only the first 32 residues of the N-terminal part [36, 37, 58] . Apart from the extension in the N-terminus of cTnI, only very short fragments of the molecule are unique to cTnI. As a result of this, the development of cTnI antibodies with no cross-reaction with skeletal isoforms is a challenging task [37] . Therefore, for a long time, the N-terminal region of cTnI (the first 32 residues) was considered to be the best site for antibody production because this sequence of amino acids is absent in the skeletal isoform of troponin I [61] [62] [63] . However, the extreme N-terminal and C-terminal ends are highly susceptible for proteolytic degradation and epitope loss resulting in vastly reduced recovery rates [61] . Therefore, advanced generations of cTnI assays used monoclonal antibodies directed against epitopes in the central, more stable part of cTnI, i.e. between residues 30 and 110 [61] . However, this region of the molecule is sensitive to interference with autoantibodies and crossreactivity. Therefore, a combination of several capture and detection antibodies is being followed as a strategy to engineer optimal assay specifications [37] .
At present, the rates of analytically true false-positive or negative cTnT or hsTnT elevation have been reported between 1 and 3% [64, 65] . Reasons include pre-analytical issues, interference with hemolysis, unspecific compounds, fibrin, biotin, rheumatoid factor, autoantibodies, heterophilic antibodies, human-anti-mouse antibodies (HAMA) or analyzer malfunction [64] . Truly false-positive or false-negative cTnT or hsTnT results are suspected in the presence of a discordance between the clinical picture and the measured cTnT or hsTnT concentration. By definition, the term "false-positive" cTnT or hsTnT is correct only when cross-reactivity with skeletal troponin is suspected. However, if re-expression of cTn in skeletal muscle is claimed as the underlying pathology, the term "falsepositive" is misleading and should be avoided because the assay correctly detects the re-expressed cTn isoform.
A higher prevalence of detectable hsTnT vs hsTnI in non-ischemic cardiac diseases has been reported [35] and is difficult to explain. There are at least three possible reasons that may in part explain the differences. First, there is some evidence [27, 28, 33] suggesting that the upper limit of normal (ULN) (99th percentile value of a healthy reference population) of the Abbott hsTnI STAT assay (99th percentile of healthy reference population) recommended by the manufacturer is too high for explaining a lower bioequivalent ULN as well as explaining a higher clinical specificity than the hsTnT assay. Second, proteolysis and posttranslational modification after the release of cTn into blood may affect detection of circulating cTnT or cTnI. Both cTnT and cTnI share in common, a centrally located epitope which is targeted by the detection antibody and which is less sensitive to epitope loss by proteolytic degradation. In addition, posttranslational changes, particularly phosphorylation and oxidation have been reported to change the configuration of the molecule. cTnI is particularly susceptible to posttranslational modifications. It has been reported that ~50% of the cTnI in the blood of AMI patients is in the phosphorylated form [65] . The structural and conformational changes following phosphorylation can significantly affect the binding of some antibodies to cTnI [61, 66] . Furthermore, the two cysteine residues in positions 80 and 97 can form a disulfide bond, allowing cTnI to be found in oxidized and reduced forms [67] , again affecting the antigen recognition of different commercially available assays [68] . Because the cTnI molecule has a high positive charge (pI 9.87), it will attract negatively charged molecules such as heparin [69] , which in turn can interfere with the antibody-antigen interaction [61] such as phosphorylation and oxidation [66, 70] . In addition, macrotroponin formation and susceptibility to autoantibody interference are more pronounced with the Abbott hsTnI STAT assay [71] . While most effects of proteolytic degradation and posttranslational changes have been reported after MI [68] , little is known in non-ischemic conditions, e.g. pressure/volume overload or inflammation.
How relevant is the problem in clinical practice?
In the US, chest pain and shortness of breath account for 13 million patient visits to an ED [72] . In contrast, the prevalence of muscular dystrophies are considerably low, ranging from six in 100,000 males for Duchenne muscular dystrophy (DMD) to 2.4 per 100,000 for Becker muscular dystrophy [73, 74] . Muscular dystrophies represent a clinically and genetically heterogeneous group of disorders including dystrophinopathies, sarcoglycanopathies (limb-girdle muscular dystrophies 2C, 2D, 2E, and 2F), glycogen storage diseases and a variety of other entities [75] . DMD and BMD are responsible for over 80% of all muscular dystrophies [44] . Clinically overt heart failure in dystrophinopathies may be delayed or absent, due to relative physical inactivity. Improved health care has increased the mean age of death from 19 to at least 25 years in patients with DMD [76] . Clinical manifestation of heart disease is variable during a lifetime and may include conduction disorder, atrial fibrillation and atrial flutter [50, 74, 75] . However, the development of dilated cardiomyopathy, sometimes may be preceded by localized hypertrophy and isolated conduction defects in DMD [77] . Patients Box 3 -The term "false-positive" troponin elevation should refer to an interference with an unspecific analyte including sTn T or I isoforms, CK, macrotroponin, biotin, fibrin, an interference with heterophilic or auto-immune antibodies, hemolysis, or an analyzer malfunction. -If -and this is hypothetical at present -the hsTnT assay detects re-expressed cTnT in the blood of patients with skeletal muscle disease, the detection has to be labeled (analytically) "true positive". -The present hsTnT (and Abbott hsTnI) show no cross-reactivity with CK in vitro and in vivo due to careful monoclonal antibody selection and assay engineering. -Therefore, the term "false-positive" hsTnT in the context of chronic skeletal muscle disease is misleading and should be deferred.
Box 4
-Muscular dystrophies, glycogen storage diseases and a variety of other entities affecting the skeletal muscle are very rare and these patients commonly die young from respiratory failure before the can manifest CAD. -Elevated hsTnT or hsTnI associated with severe chronic kidney disease, older age or underlying structural heart disease is more prevalent and constitutes a more relevant confounder for the diagnosis of NSTEMI. -In this context, serial troponin measurements help to discriminate between chronic and acute myocardial injury.
with skeletal muscle disease usually demonstrate a stable and modest elevation of cTnT and only rarely manifest a rising and/or falling pattern of cTnT or hsTn. For all those reasons, the relevance of troponin expression in skeletal muscle disease is clearly overrated compared to more prevalent and clinically relevant confounders such as older age, chronic kidney disease or co-existing structural heart disease. Moreover, baseline elevations of cTnT or hsTnT in skeletal muscle disease are unlikely to confound the diagnosis of MI which is based on an acute rise and or fall of cTn or hsTn [2] .
Summary
At present, there are several potential reasons for elevated cTn, particularly hsTn among patients with chronic skeletal muscle disease ( Figure 2 ). In particular, the exact mechanism for elevated hsTnT and less frequently hsTnI in muscular dystrophies is unsettled and a hypothesis claiming re-expression of fetal cTnT in chronic regenerating skeletal muscle is not consistently supported. Although, the existence of a re-expressed cTn in regenerating skeletal muscle cannot be ruled-out beyond doubt, the probability that elevated cTnT is truly indicating myocardial injury is more likely than the probability that elevations are a consequence of inappropriate cardio-specificity or cross-reactivity with CK, even if a cardiac imaging study is normal.
Reasons for the discordant prevalence of cTnT and cTnI in chronic skeletal muscle diseases remain unclear and prompt the direct comparison between hsTnT and other hsTnI assays to overcome selection bias or comparison of assays with different high sensitivity designation. 
